Working… Menu

C1-INH Compared to Placebo at the Time of Prodromal Symptoms for Hereditary Angioedema (HAE) Exacerbation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01151735
Recruitment Status : Withdrawn (PennState would not allow the study to move forward)
First Posted : June 28, 2010
Last Update Posted : November 30, 2012
Information provided by (Responsible Party):
Timothy Craig, Penn State University

Brief Summary:
The study hypothesis is that treatment of Hereditary Angioedema at the time of prodromal symptoms will decrease morbidity associated with the disease

Condition or disease Intervention/treatment Phase
Hereditary Angioedema Drug: C-1-esterase Drug: placebo Phase 4

Detailed Description:

Section 3 Study Design and Methods:

Our proposal is to perform a randomized double-blind, three-arm, three-way cross-over study in which subjects with HAE would be placed into one of three different treatment groups based on computer randomization. Subjects will be randomized to receive placebo, 1000 units, or 1500 units of C1-INH at the onset of prodromal symptoms although they would be blinded to which one they were receiving. Randomization will be to one of the two doses or placebo and the sequence of further treatments will be determined randomly in a double-blinded fashion by a person who is not involved in the study. The randomized drug will be available 24 hours and 7 days a week. They would have to come to the study office to receive the blinded drug, and would need to seek treatment within 6 hours of the onset of the prodrome. Following the blinded treatment, the subject would need to be observed for at least 30 minutes. If a subject develops an acute HAE exacerbation in any of the three treatment periods, they would have access to 20 units/kg of open label C1-INH for acute treatment also received at the study office, and the time from onset of symptoms of an acute attack until the time the subject sought open-label treatment could not exceed 12 hours. Following open label rescue, the subject would need to be observed for at least 1 hour or until symptoms started to improve. The subject would also be expected to complete a symptom diary card over the next 24 hours after receiving open-label C1-INH to monitor severity and duration of symptoms (24 Hour Prodrome/Open-Label Diary Appendix IV) associated with the acute attack. The number, duration, and severity of acute HAE attacks would be compared for each treatment period. Each treatment period would last 16 weeks so each subject would be studied for a total of 48 weeks. Because safety has been established when C1-INH is used every third day with prophylaxis therapy, and patients may receive C1-INH for an attack without limits on the closeness of the attacks, our patients in this study may be retreated for prodromal symptoms as they require it, but not more than every other day since prodromes may precede the swelling and abdominal pain by up to 2 days.

Thrombosis has been identified with C1-INH, but only in neonates who were premature and at much higher doses than 1500 units every third day. Cinryze, also a C1-INH, is FDA approved for 1000 units every third day for prophylaxis. The dosing used in our study reflects the FDA approval dosing for Berinert, which is 20 units per kg for acute therapy, so that most patients will receive 1000 to 2500 units of C1-inh whenever they have an attack without day restrictions between dosing. The dosage approved by the FDA is 20 units per kg for Berinert and 1000 units total dose for Cinryze. The dose used in our study approximates these doses, but is not an FDA approved dose. There are no limits on how often Berinert can be dosed for acute attacks.

Figure IV outlines our treatment protocol.

Figure IV: Three-arm, randomized, cross-over, double-blind, placebo-controlled trial to determine effect of treating prodromal symptoms with C1-INH infusions of 1000 units, or 1500 units versus placebo. The sequence is random and double-blinded.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Determine the Efficacy of 1000u, and 1500u of C1-INH Compared to Placebo at the Time of Prodromal Symptoms in Preventing an Acute HAE Exacerbation.
Study Start Date : July 2010
Actual Primary Completion Date : July 2012
Actual Study Completion Date : July 2012

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: C-1-esterase inhibitor 1000 units
1000 units of C-1-esterase inhibitor given at time of prodromal symptoms
Drug: C-1-esterase
1000 units of C-1-esterase inhibitor
Other Name: low dose intervention

Active Comparator: 1500 units of C-1-esterase inhibitor
treatment with 1500 units of C-1-esterase inhibitor IV at the time of prodromal symptoms to decrease risk of exacerbation of HAE
Drug: C-1-esterase
1500 units of C-1-esterase inhibitor
Other Name: high dose intervention

Placebo Comparator: placebo injection
placebo injection given for prodromal symptoms as double blinded therapy
Drug: placebo
Other Name: placebo arm

Primary Outcome Measures :
  1. percentage of full blown HAE attacks occurring within 24 hours following treatment at the prodromal [ Time Frame: 24 hours ]
    To compare the percentage of full blown HAE attacks occurring within 24 hours following treatment at the prodromal stage of an attack using placebo or one of two doses of C1-INH.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Documented HAE type 1 or 2 by C4 level and C1-INH level or function.
  2. Able to read, understand, and sign informed consent.
  3. Above the age of 12 years.
  4. Willing to complete daily diary.
  5. Have at least 1 HAE exacerbations per month averaged over the last 6 months.
  6. Prodromal symptoms will not be an inclusion or exclusion since if used it would bias our ability to determine specificity and sensitivity of prodromal symptoms.
  7. Present for treatment within 6 hours of onset of prodromal symptoms.
  8. Treatment for an acute attack can be given at any time without restriction.

Exclusion Criteria:

  1. Inability to read English.
  2. Prior adverse effects to C1-INH.
  3. Participation in alternate investigational drug trial.
  4. Diabetes, neurologic diseases, cardiac diseases, dermatologic diseases that may have associated symptoms that mimic prodromal symptoms.
  5. Inability to withdraw from androgens or C1-INH prophylaxis.
  6. Pregnant or breast feeding mothers.
  7. Prisoners or other institutionalized individuals.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01151735

Sponsors and Collaborators
Penn State University
Layout table for investigator information
Principal Investigator: Michael Lunn, DO Penn State University

Layout table for additonal information
Responsible Party: Timothy Craig, Principal Investigator, Penn State University Identifier: NCT01151735     History of Changes
Other Study ID Numbers: IRB#33225
First Posted: June 28, 2010    Key Record Dates
Last Update Posted: November 30, 2012
Last Verified: November 2012
Keywords provided by Timothy Craig, Penn State University:
Hereditary Diseases
Orphan Disease
Additional relevant MeSH terms:
Layout table for MeSH terms
Angioedemas, Hereditary
Prodromal Symptoms
Vascular Diseases
Cardiovascular Diseases
Skin Diseases, Vascular
Skin Diseases
Hypersensitivity, Immediate
Immune System Diseases
Genetic Diseases, Inborn
Signs and Symptoms
Complement C1s
Complement C1 Inhibitor Protein
Complement C1 Inactivator Proteins
Immunologic Factors
Physiological Effects of Drugs
Complement Inactivating Agents
Immunosuppressive Agents